Biomea Fusion (BMEA)
NASDAQ:BMEA
Want to see BMEA full AI Analyst Report?
BMEA Stock Chart & Stats
$2.21
$0.07(1.75%)
At close: 4:00 PM EST
$2.21
$0.07(1.75%)
Day’s Range― - ―
52-Week Range$0.87 - $2.99
Previous CloseN/A
Volume309.16K
Average Volume (3M)2.40M
Market Cap
$85.31M
Enterprise Value$27.94M
Total Cash (Recent Filing)$44.69M
Total Debt (Recent Filing)$1.24M
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Aug 03, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.89
Shares Outstanding72,299,440
10 Day Avg. Volume5,869,688
30 Day Avg. Volume2,395,415
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-0.92
Enterprise Value/Market Cap0.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-47.12
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$7.20Price Target Upside225.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
R&D Platform: Covalent Small-molecule ExpertiseBiomea's platform focus on covalent small-molecule inhibitors is a durable competitive asset: it can produce differentiated mechanisms of action and multiple pipeline candidates. A platform-centric model raises probability of repeatable product opportunities and licensing/partnership optionality over time.
Positive Phase 2 T1D Data For IcovamenibRobust 52-week proof-of-concept in T1D represents a structural clinical validation beyond oncology. The differentiated beta cell biology approach could expand the addressable market and support longer development programs, collaborator interest, and strategic options beyond initial indications.
Low Financial LeverageModest debt levels reduce near-term solvency risk and provide financing flexibility for R&D investment. Low leverage increases the company's capacity to raise additional capital through equity or partnerships without immediate covenant pressure, a durable balance-sheet strength for a clinical-stage firm.
Bears Say
Pre-commercial: Zero RevenueAs a pre-commercial biotech with no product sales, Biomea depends on external financing or partnerships to fund operations. This structural revenue absence means long-term viability hinges on successful trials, deal-making, or recurrent capital raises, increasing funding and execution risk.
Sharply Eroded Equity/capital BaseSignificant equity erosion materially reduces financial flexibility and magnifies dilution or refinancing risk. A much smaller capital base limits the cushion for further losses, heightening dependence on new financing and increasing the likelihood of dilutive transactions or constrained strategic choices.
Persistent Negative Operating And Free Cash FlowOngoing cash burn, albeit improved, shows losses translate into real cash outflows (free cash flow tracks net loss ~1.0). Continued negative cash generation forces reliance on capital markets or partners, creating execution and dilution risk until a sustainable cash-positive business model or partnership revenue emerges.
Biomea Fusion News
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $0.87 and its highest was $2.99 in the past 12 months.
What is Biomea Fusion’s market cap?
Biomea Fusion’s market cap is $85.31M.
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Aug 03, 2026 which is in 44 days.
How were Biomea Fusion’s earnings last quarter?
Biomea Fusion released its earnings results on May 06, 2026. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.231 by $0.061.
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate is -0.22.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 72,299,440 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Biomea Fusion reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.231. Following the earnings report the stock price went up 1.875%.
Which hedge fund is a major shareholder of Biomea Fusion?
Currently, no hedge funds are holding shares in BMEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biomea Fusion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.20 (225.79% Upside)
$7.20 (225.79% Upside)
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.77%
12-Months-Change
Fundamentals
Return on Equity
-196.72%
Trailing 12-Months
Asset Growth
-15.75%
Trailing 12-Months
Company Description
Biomea Fusion
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.
BMEA Stock 12 Month Forecast
Average Price Target
$7.20
▲(225.79% Upside)
Technical Analysis
Ownership Overview
8.66% Insiders
11.28% Mutual Funds
5.16% Other Institutional Investors
70.87% Public Companies and
Individual Investors